The international surgical journal with global reach

Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. The COMPASS Trial. Circulation 2019; 140: 529-537

Published: 15th June 2020

Authors: Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK et al.


This study included over 27,000 patients with heart failure. Compared to aspirin alone, the combination of aspirin with twice-daily rivaroxaban reduced major adverse cardiovascular events: hazard ratio 0.68, 95 per cent confidence interval 0.53 to 0.86. Major adverse event rates were similar.

Pubmed Link